[Form 4] Seres Therapeutics, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Seres Therapeutics officer Brady Kelly reported routine equity compensation activity and a small tax-related sale. On May 15, 2026, Kelly exercised restricted stock units, converting 180 shares in total into common stock at a stated price of $0.00 per share. The filing explains that each restricted stock unit is a right to receive one share of Seres common stock and describes quarterly vesting schedules for grants that began vesting on February 15, 2024 and February 15, 2025. On May 18, 2026, Kelly sold 59 shares of common stock at $7.53 per share, specifically to cover taxes tied to the RSU vesting. Following these transactions, Kelly directly holds 8,562 shares of common stock, indicating that the sale was small relative to the overall position.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 59 | $7.53 | $444.27 |
| Exercise | Restricted Stock Units | 89 | $0.00 | -- |
| Exercise | Restricted Stock Units | 91 | $0.00 | -- |
| Exercise | Common Stock | 180 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Represents shares sold to cover taxes in connection with the vesting of the restricted stock units. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.